Model-informed Dolutegravir Dose Selection in Pediatrics With First-generation INSTI Resistance
|
Twice-daily dosing of Dolutegravir is approved for adults
with HIV and integrase strand transfer inhibitor resistance, but not
for children. |
Ministry approves long-acting HIV prevention drug for rollout
The injection is given once every six months and prevents HIV infection even in unprotected sex. View article...